SVCM
CTNM

Saturn V Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Saturn V Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-319,348
Closed -$1.27M – 26
2025
Q2 		$1.27M Sell
319,348
-241,631
-43% -$1.05M 0.51% 21
2025
Q1 		$3.92M Sell
560,979
-12,043
-2% -$110K 1.98% 15
2024
Q4 		$8.39M Buy
573,022
+495,725
+641% +$7.85M 3.29% 14
2024
Q3 		$1.48M Buy
77,297
+4,466
+6% +$85.6K 0.53% 23
2024
Q2 		$1.28M Buy
+72,831
New +$1.17M 0.48% 26

Other funds holding CTNM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Saturn V Capital Management's CTNM Position: Q3 2025 in Review

Saturn V Capital Management sold out of Contineum Therapeutics (CTNM) in Q3 2025, closing a stake of 319,348 shares — an estimated $1.27M sold.

Saturn V Capital Management first reported a position in CTNM in Q2 2024 and held it in 5 quarters. The position peaked at $8.39M in Q4 2024. 62 funds tracked by Wall St. Rank hold CTNM as of Q3 2025.

  • Saturn V Capital Management reported no remaining Contineum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 319,348 Contineum Therapeutics shares in Q3 2025, an estimated $1.27M.
  • Saturn V Capital Management first reported a position in Contineum Therapeutics in Q2 2024 and held it in 5 quarters.
  • Saturn V Capital Management's Contineum Therapeutics position peaked at $8.39M in Q4 2024.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2025.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.